Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post-menopause Clear all
Recruiting Phase 4 Interventional

Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

NCT07136415
View directory record Official record
Conditions
Menopausal Women, Insomnia
Interventions
Cognitive behavioral therapy for insomnia (CBT-i), Trazodone, Daridorexant
Behavioral · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Boston, Massachusetts • Novi, Michigan • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 13, 2026, 7:38 PM EDT
Completed No phase listed Observational

Effects of Aromatase Inhibitor Therapy on Muscle Function

NCT03581552
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female
Interventions
Not listed
Lead sponsor
Tarah J Ballinger, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Sep 13, 2026, 7:38 PM EDT
Recruiting Not applicable Interventional

GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women

NCT06813261
View directory record Official record
Conditions
Postmenopause, Metabolism, Geroscience
Interventions
GLYLO, Placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 13, 2026, 7:38 PM EDT
Recruiting No phase listed Observational

Endometrial Cancer Vaginal Fluid Specimen Collection Study

NCT07544680
View directory record Official record
Conditions
Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions
Not listed
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Results available

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

NCT00696072
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Dasatinib, Letrozole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
27
States / cities
Sedona, Arizona • Tucson, Arizona • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

NCT01732770
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Placebo to Denosumab, Placebo to Zoledronic Acid
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Santa Monica, California • Lakewood, Colorado • Longmont, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Results available

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

NCT05549505
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471, Anastrozole, Surgical resection of breast tumor
Drug · Procedure
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 2 Interventional

Phytoestrogens and Memory Decline in Menopause

NCT00051402
View directory record Official record
Conditions
Memory Loss, Postmenopause
Interventions
Isoflavones
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
62 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2007 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 3 Interventional

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

NCT00232661
View directory record Official record
Conditions
Breast Cancer
Interventions
ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older · Female only
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
13
States / cities
Santa Rosa, California • New Britain, Connecticut • Torrington, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2010 · Synced Sep 13, 2026, 7:38 PM EDT
Completed No phase listed Observational

Intestine Bacteria and Breast Cancer Risk

NCT01461070
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
50 Years to 69 Years · Female only
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Sep 13, 2026, 7:38 PM EDT
Recruiting Phase 1 Interventional

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

NCT07401381
View directory record Official record
Conditions
Hormone Receptor Positive Early Breast Cancer
Interventions
US-sourced oral Femara® + Letrozole SIE, EU sourced oral Femara® + Letrozole SIE
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Beverly Hills, California • Margate, Florida
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Following Lipectomy to Understand Adipose Tissue Re-accumulation

NCT00995631
View directory record Official record
Conditions
Menopause, Pre-menopause
Interventions
Femoral lipectomy
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
35 Years to 60 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

NCT01808040
View directory record Official record
Conditions
Post Menopausal, Hormone Receptor Positive Breast Cancer
Interventions
TAK700
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 13, 2026, 7:38 PM EDT
Recruiting Not applicable Interventional

BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women

NCT07413705
View directory record Official record
Conditions
Depressive Symptoms, Urinary Incontinence, Sexual Dysfunction
Interventions
EXOMIND (BTL-699-2) Active Treatment, EMSELLA (HPM-6000UF) ActiveTreatment, EXOMIND (BTL-699-2) Sham Treatment, EMSELLA (HPM-6000UF) Sham Treatment
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
40 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Winter Garden, Florida • Wellesley, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 13, 2026, 7:38 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

NCT07218445
View directory record Official record
Conditions
Obesity, Menopause Hot Flashes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 60 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biomarkers in Post-Menopausal Women Receiving Flaxseed

NCT01698294
View directory record Official record
Conditions
No Evidence of Disease
Interventions
Clinical Observation, Flaxseed, Laboratory Biomarker Analysis, Questionnaire Administration
Other · Dietary Supplement
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
45 Years to 80 Years · Female only
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Results available

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

NCT00530868
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast, Breast Neoplasm
Interventions
Letrozole (Femara), Letrozole; Avastin
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
7
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Combination Osteogenic Therapy in Established Osteoporosis

NCT00018447
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
PTH 1-34, MFPSR-fluoride
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years to 80 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Not applicable Interventional

A Study Evaluating the Effects of Topical Clitoral Estradiol Cream in Post Menopausal Women

NCT02859285
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo vulvar cream, Estradiol vulvar cream
Other
Lead sponsor
ProHealth Care, Inc
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 3 Interventional Results available

3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs

NCT00718861
View directory record Official record
Conditions
Post-menopausal Osteoporosis
Interventions
Placebo, Zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
San Diego, California • Lakewood, Colorado • Gainesville, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause

NCT00009659
View directory record Official record
Conditions
Postmenopause
Interventions
CDB 2914
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 13, 2026, 7:38 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Dairy Choline Bioavailability

NCT06902480
View directory record Official record
Conditions
Post-menopausal Women, Post-menopausal Status
Interventions
WPPC, Whole egg powder
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
51 Years to 70 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 13, 2026, 7:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Role of T-cells in Post-Menopausal Osteoporosis

NCT00787904
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 13, 2026, 7:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women

NCT02010593
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Dapivirine Vaginal Ring, Placebo Vaginal Ring
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 13, 2026, 7:38 PM EDT